IDENTIFICATION OF PROSTAGLANDIN-E RECEPTOR EP2 CLONED FROM MASTOCYTOMA-CELLS AS EP4 SUBTYPE

被引:139
作者
NISHIGAKI, N
NEGISHI, M
HONDA, A
SUGIMOTO, Y
NAMBA, T
NARUMIYA, S
ICHIKAWA, A
机构
[1] KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN
[2] KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN
关键词
PROSTAGLANDIN E; EP4; SUBTYPE; PROSTANOID RECEPTOR;
D O I
10.1016/0014-5793(95)00421-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We previously cloned a cDNA for a mouse PGE receptor positively coupled to adenylate cyclase from mouse mastocytoma cells, and reported it as EP2 subtype of PGE receptor [Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S. and Ichikawa, A. (1993) J. Biol. Chem. 268, 7759-7762]. However, it is not sensitive to one of the EP2 agonists, butaprost. Recently another subtype of PGE receptor coupled to adenylate cyclase has been identified pharmacologically and named EP4. These findings have led us to examine whether the cloned receptor is the EP4 subtype. AH23848B, a selective EP4 antagonist, not only displaced the [H-3]PGE(2) binding to the cloned receptor but antagonized the PGE(2)-stimulated cAMP formation in the receptor. In contrast, EP2 specific agonists, butaprost and 19(R)OH-PGE(2) neither bound to the receptor nor stimulated the cAMP formation. These results suggest that this receptor previously reported as 'EP2' subtype is identical to the pharmacologically defined EP4 subtype and not of EP2 subtype.
引用
收藏
页码:339 / 341
页数:3
相关论文
共 21 条
[1]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[2]   SYNTHESIS AND GASTRIC ANTISECRETORY PROPERTIES OF ALLENIC 16-PHENOXY-OMEGA-TETRANOR PROSTAGLANDIN-E ANALOGS [J].
CARPIO, H ;
COOPER, GF ;
EDWARDS, JA ;
FRIED, JH ;
GARAY, GL ;
GUZMAN, A ;
MENDEZ, JA ;
MUCHOWSKI, JM ;
ROSZKOWSKI, AP ;
VANHORN, AR ;
WREN, D .
PROSTAGLANDINS, 1987, 33 (02) :169-180
[3]  
COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P
[4]  
COLEMAN RA, 1994, PROSTAGLANDINS, V47, P152
[5]  
COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643
[6]   PROSTAGLANDIN-E RECEPTOR SUBTYPES IN SMOOTH-MUSCLE - AGONIST ACTIVITIES OF STABLE PROSTACYCLIN ANALOGS [J].
DONG, YJ ;
JONES, RL ;
WILSON, NH .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (01) :97-107
[7]   INSULIN-DEPENDENT CONTRACTILITY OF GLOMERULAR MESANGIAL CELLS IN RESPONSE TO ANGIOTENSIN-II, PLATELET-ACTIVATING-FACTOR AND ENDOTHELIN IS ATTENUATED BY PROSTAGLANDIN-E2 [J].
DUNLOP, ME ;
LARKINS, RG .
BIOCHEMICAL JOURNAL, 1990, 272 (03) :561-568
[8]   LIPOFECTION - A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE [J].
FELGNER, PL ;
GADEK, TR ;
HOLM, M ;
ROMAN, R ;
CHAN, HW ;
WENZ, M ;
NORTHROP, JP ;
RINGOLD, GM ;
DANIELSEN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7413-7417
[9]  
FERRERI NR, 1992, J BIOL CHEM, V267, P9443